Metabolic X (Reta x Cangri)

Metabolic X (Reta x Cangri) 10 mg is PrimeTime BioLabs' combined-agonist research vial, containing two distinct investigational peptides — retatrutide and cagrilintide — at a stated total peptide mass of 10 mg per vial. The vial is packaged as a single-use, lyophilized preparation, sealed and light-protected to preserve peptide integrity during shipping and storage, with a lot-specific label for batch traceability. Retatrutide and cagrilintide act on different receptor systems: retatrutide as a triple agonist at GIP, GLP-1, and glucagon receptors, and cagrilintide as an amylin receptor agonist. Combining them in one vial lets researchers study incretin- and amylin-pathway activation side by side within a single sample, rather than sourcing and pairing two separate materials. This product is intended strictly for in-vitro laboratory research use by qualified personnel, and is not formulated, labeled, or sold for any other purpose.

Retatrutide Retatrutide (development code LY3437943) is an investigational peptide engineered to activate the GIP, GLP-1, and glucagon receptors simultaneously. This triple-agonist profile is the subject of ongoing clinical investigation into effects on appetite signaling, energy expenditure, and lipid metabolism. Retatrutide has advanced through late-stage clinical trials as a standalone compound; that evidence describes retatrutide on its own, not this specific research blend. Cagrilintide Cagrilintide (development code AM833) is an investigational long-acting amylin analogue. It acts at amylin receptors, a mechanism studied for its influence on gastric emptying and satiety signaling. Much of cagrilintide's published clinical evidence comes from trials of cagrilintide combined with semaglutide — a different combination than the one in this product — so that evidence describes cagrilintide alongside semaglutide, not cagrilintide alongside retatrutide. Evidence boundary Retatrutide's research record and cagrilintide's research record are each substantial on their own. Neither record was generated using this specific retatrutide-plus-cagrilintide research vial, and no published clinical studies have directly evaluated this exact combination. Findings about retatrutide alone, or about cagrilintide paired with semaglutide, should not be read as evidence about Metabolic X. This vial is supplied so that researchers can investigate the combined mechanism themselves under controlled laboratory conditions.

Metabolic X (Reta x Cangri) 10 mg carries a stated purity of 99%+. Each lot is third-party tested for purity, identity, and sterility. A Certificate of Analysis (COA) matching the batch number on the vial is available for download, so researchers can confirm the specifications of the exact lot they received before use. The current reference batch (PTB-METX-10MG-0925) was analyzed on 8/27/2026 at 99% purity. Purity testing quantifies how much of the material is the intended peptide versus other substances; identity testing confirms the material matches the expected peptide; sterility testing checks for microbial contamination. These results describe the analytical profile of a given batch — they do not constitute evidence of safety or efficacy for any use. Store the lyophilized vial in a freezer at -20°C, protected from light. Once reconstituted for laboratory use, keep refrigerated at 2–8°C and use within the timeframe noted on that batch's COA.

Research Use Only. Metabolic X (Reta x Cangri) 10 mg is distributed exclusively for qualified laboratory research purposes and must be handled only by trained laboratory personnel. This product is not a drug, dietary supplement, or cosmetic. It carries no FDA approval and is not intended for human or animal consumption, diagnosis, or therapeutic use of any kind. Retatrutide and cagrilintide are investigational compounds. As of this writing, neither is a component of an FDA-approved drug, and neither has been found safe and effective by the FDA for any condition. This listing does not constitute medical, legal, or regulatory advice.